中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2010, Vol. 45 Issue (15) :1187-1189    DOI:
ҩ�����ٴ� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
��1��������ëù������ȷ����̺ͷ���������Ч���ƵĻع˷���
���ξ�a����Сëb��������b���ﴺ��a
����������ҽԺ��a.�ٴ�ҩѧ�ң�b.�����ƣ����� 100730

Download: PDF (922KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ���ٴ���ʵ������ѧϰ������ëù����Ⱦȷ��Ҫ�㣬��������׶Դ�ͳ��������ù��BΪ���ĵĿ�ëù����Ⱦ������˼·�ͷ�������������࿹���ҩ������ëù����Ⱦ�Ŀ����Խ���̽�֣����ٴ��ο������� ͨ����1����ëù����Ⱦ������Ϻ����ƹ��̵Ļع��Է������������Ϯ�Էβ������Ⱦ��ȷ��Ҫ������Ͷ�ҩ������˼·��̽�֡���� ���߷�ëù����Ⱦ�õ�ȷ��ٴ�ʵ���з��ֱ���ëù����Ⱦ����Ӧ�÷�������������Ч���������Ҳ��ʾ�����ȶ���ת������ ��ëù����Ⱦ���գ�ȷ�ﲡ����������ϱ������ƾ��飬�ٴ����Կ���Ӧ�÷�������������࿹���ҩ������ëù����Ⱦ��
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� ��ëù����   ��������   ����ù��B     
Abstract�� OBJECTIVE To establish quality standard of Fuzi and Fupian by TLC and HPLC method. METHODS Diester aconitium alkaloids in Fuzi and monoester aconitium alkaloids in Fupian were identified by TLC method. The limit examination of monoester aconitium alkaloids and determination of diester aconitium alkaloids in Fuzi were carried out by HPLC method simultaneously. The limit examination of diester aconitium alkaloids and determination of monoester aconitium alkaloids in Fupian were carried out by HPLC method simultaneously. RESULTS Clear spots were obtained with good separation in TLC identification. For 6 aconitium alkaloids, calibration curves were linear in the range of 5-100 ��g��mL-1, the limits of detection were 1 ��g��mL-1 and recoveries were between 95%-105%. CONCLUSION The proposed method is exclusive, accurate and applicable for control of Fuzi and Fupian quality.
Keywords��   
�ո�����: 2012-01-01;
���ñ���:   
.��1��������ëù������ȷ����̺ͷ���������Ч���ƵĻع˷���[J]  �й�ҩѧ��־, 2010,V45(15): 1187-1189
.[J]  Chinese Pharmaceutical Journal, 2010,V45(15): 1187-1189
��
[1] MU X D. Diagnosis and therapeutics of pulmonary mucormycosis[J]. Chinese Community Doctors���й�����ҽʦ���� 2008�� 24(8)�� 14.[2] DANNAOUI E�� MELETIADIS J�� MOUTON J W�� et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals[J]. J Antimicrob Chemother��2003�� 51��1���� 45-52.[3] VITALE R G�� MEIS J F�� MOUTON J W�� et al. Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media[J]. J Antimicrob Chemother�� 2003�� 52��1���� 65-70.[4] HERBRECHT R. Posaconazole�� a potent�� extended-spectrum triazole anti-fungal for the treatment of serious fungal infections[J]. International J Clin Practi�� 2004�� 58��6���� 612-624.[5] SUN Q N�� NAJVAR L K�� BOCANEGRA R�� et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model[J]. Antimicrob Agents Chemother�� 2002�� 46(7)�� 2310-2312.[6] HARADA A S�� LAU W. Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole[J]. Hawaii Med J�� 2007�� 66(3)��68-71.[7] GELSTON C D�� DURAIRAJ V D�� SIMOES E A. Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole[J]. Arch Ophthalmol�� 2007�� 125(6)�� 848-849.[8] WRAY J D�� SPARKES A H�� JOHNSON E M. Infection of the subcutis of the nose in a cat caused by Mucor species�� successful treatment using posaconazole[J]. J Feline Med Surg�� 2008�� 10(5)�� 523-527.[9] PAGE RL 2ND�� SCHWIESOW J�� HILTS A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis�� case report and review of the literature[J]. Pharmacotherapy�� 2007�� 27(2)�� 290-298.[10] SEDLACEK M�� COTTER J G�� SURIAWINATA A A�� et al. Mucormycosis peritonitis�� more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B[J]. Am J Kidney Dis�� 2008�� 51(2)�� 302-306.[11] CHAMILOS G�� LEWIS R E�� KONTOYIANNIS D P. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole[J]. Antimicrob Agents Chemother�� 2006�� 50(1)��96-103.[12] GIL-LAMAIGNERE C�� HESS R�� SALVENMOSER S�� et al. Effect of media composition and in vitro activity of posaconazole�� caspofungin and voriconazole against zygomycetes[J]. J Antimicrob Chemother�� 2005�� 55(6)�� 1016-1019.[13] MULLER F M�� KURZAI O�� HACKER J�� et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis[J]. J Antimicrob Chemother�� 2001�� 48��5���� 713-715.[14] PAPPAS P G�� KAUFFMAN C A�� ANDES D�� et al.Clinical practice guidelines for the management of candidiasis�� 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(5)��503-535.
[1] ������ ������.����ù��B/���Ҷ���-���춬��������Ƕ�ι��������׽������Ʊ�������[J]. �й�ҩѧ��־, 2010,45(5): 359-364
[2] ����ƽ;����;����;����;л��.����ù��B΢����Ʊ������⾭Ƥ��͸�о�[J]. �й�ҩѧ��־, 2009,44(04): 283-287
[3] ��ΰ;��÷��;��ϸ��;���Ӷ�.��ЧҺ��ɫ�׷��ⶨ��������ù��B����Һ�ĺ���[J]. �й�ҩѧ��־, 2008,43(17): 1352-1353
[4] �Ƴɿ�;�����;������;����˳.���������ɢƬ���������Ч���о�[J]. �й�ҩѧ��־, 2007,42(16): 1241-1243
[5] ��׿��;���ΰ;��ܰ��;����.����ù��B�ľ��Ҷ���-�����ὺ�����Ʊ����������ͷŶ���ѧ[J]. �й�ҩѧ��־, 2007,42(07): 519-523
[6] ����;������;�ž���;����÷;��ΰ��;������.����ù��B��ѭ�����������о�[J]. �й�ҩѧ��־, 2005,39(15): 1156-1159
[7] ��С����л����������.�������ἰ�������������ù��B֬��������Ѫ�����ϵ�����[J]. �й�ҩѧ��־, 2003,38(08): 598-601
[8] ������ �ϱ�ϼ ������.����ù��B֬��������Ƽ�����������[J]. �й�ҩѧ��־, 2000,35(09): 593-595
[9] ������;κ����.֬������Ϊҩ������ϵͳ��Ӧ��[J]. �й�ҩѧ��־, 1999,34(03): 145-147
[10] �޶�; ����; ������; ������; ������; ����.����ù��B��50g��L-1������ע��Һ���ȶ��Կ���[J]. �й�ҩѧ��־, 1998,33(04): 220-222
Copyright 2010 by �й�ҩѧ��־